Hassan Fouayzi

Dr. Hassan Fouayzi

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
KFKimberly A. Fisher
Kimberly A. Fisher
SBSarah J. Bloomstone
Sarah J. Bloomstone
JWJeremy Walder
Jeremy Walder
SCSybil Crawford
Sybil Crawford
HFHassan Fouayzi
Hassan Fouayzi
KMKathleen M. Mazor
Kathleen M. Mazor
Coronavirus disease 2019 (COVID-19) has rapidly instigated a global pandemic. Vaccine development is proceeding at an unprecedented pace. Once available, it will be important to maximize vaccine uptake and coverage. To assess intent to be vaccinated against COVID-19 among a representative sample of adults in the United States and identify predictors of and reasons for vaccine hesitancy. Cross-sectional survey, fielded from 16 through 20 April 2020. Representative sample of adults residing in the United States. Approximately 1000 adults drawn from the AmeriSpeak probability-based research panel, covering approximately 97% of the U.S. household population. Intent to be vaccinated against COVID-19 was measured with the question, "When a vaccine for the coronavirus becomes available, will you get vaccinated?" Response options were "yes," "no," and "not sure." Participants who responded "no" or "not sure" were asked to provide a reason. A total of 991 AmeriSpeak panel members responded. Overall, 57.6% of participants (n = 571) intended to be vaccinated, 31.6% (n = 313) were not sure, and 10.8% (n = 107) did not intend to be vaccinated. Factors independently associated with vaccine hesitancy (a response of "no" or "not sure") included younger age, Black race, lower educational attainment, and not having received the influenza vaccine in the prior year. Reasons for vaccine hesitancy included vaccine-specific concerns, a need for more information, antivaccine attitudes or beliefs, and a lack of trust. Participants' intent to be vaccinated was explored before a vaccine was available and when the pandemic was affecting a narrower swath of the United States. Questions about specific information or factors that might increase vaccination acceptance were not included. The survey response rate was 16.1%. This national survey, conducted during the coronavirus pandemic, revealed that approximately 3 in 10 adults were not sure they would accept vaccination and 1 in 10 did not intend to be vaccinated against COVID-19. Targeted and multipronged efforts will be needed to increase acceptance of a COVID-19 vaccine when one becomes available. Agency for Healthcare Research and Quality.

27 March 2009 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
LHLeslie R Harrold
Leslie R Harrold
SASusan E Andrade
Susan E Andrade
BBBecky A Briesacher
Becky A Briesacher
MRMarsha A Raebel
Marsha A Raebel
HFHassan Fouayzi
Hassan Fouayzi
IOIra S Ockene
Ira S Ockene
Introduction: Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout. Methods: We identified persons using two integrated delivery systems aged 18 years or older with a diagnosis of gout who initiated use of allopurinol, probenecid or sulfinpyrazone from 1 January 2000 to 30 June 2006. Non-adherence was measured using the medication possession ratio (MPR) over the first year of therapy and defined as an MPR < 0.8. Descriptive statistics were calculated and logistic regression was used to estimate the strength of the association between patient characteristics and non-adherence. Results: A total of 4,166 gout patients initiated ULDs; 97% received allopurinol. Median MPR for any ULD use was 0.68 (interquartile range (IQR) 0.64). Over half of the patients (56%) were non-adherent (MPR < 0.8). In adjusted analyses, predictors of poor adherence included younger age (odds ratio (OR) 2.43, 95% confidence interval (CI) 1.86 to 3.18 for ages <45 and OR 1.44, 95% CI 1.08 to 1.93 for ages 45 to 49), fewer comorbid conditions (OR 1.46, 95% CI 1.20 to 1.77), no provider visits for gout prior to urate-lowering drug initiation (OR 1.28, 95% CI 1.05 to 1.55), and use of non-steroidal anti-inflammatory drugs in the year prior to urate-lowering drug initiation (OR 1.15, 95% CI 1.00 to 1.31). Conclusions: Non-adherence amongst gout patients initiating ULDs is exceedingly common, particularly in younger patients with less comorbidity and no provider visits for gout prior to ULD initiation. Providers should be aware of the magnitude of non-adherence with ULDs.

20 January 2011 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
BBBecky A Briesacher
Becky A Briesacher
AQAlexandra L Quittner
Alexandra L Quittner
LSLisa Saiman
Lisa Saiman
PSPatricia Sacco
Patricia Sacco
HFHassan Fouayzi
Hassan Fouayzi
LQLynne M Quittell
Lynne M Quittell
Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization.

26 April 2010 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
BBBecky A. Briesacher
Becky A. Briesacher
SSStephen B. Soumerai
Stephen B. Soumerai
TFTerry S. Field
Terry S. Field
HFHassan Fouayzi
Hassan Fouayzi
JGJerry H. Gurwitz
Jerry H. Gurwitz
Controversy continues to surround the safety of benzodiazepine use in nursing homes (NHs), even though as many as 30% of residents receive these agents.1 Benzodiazepine medications have well-documented sedative effects that can impair cognition and balance and produce daytime somnolence.2 Benzodiazepines have also been associated with an increased risk of falls and fractures in NHs, although the findings are inconsistent.3-6 In addition, abrupt discontinuation of benzodiazepine use, especially after long-term use, has been associated with confusion, elevated systolic blood pressure, and, in rare cases, seizures.7-9 However, no data have indicated that policies to limit benzodiazepine use in older, institutionalized adults result in reduced risk of falls and injury.7,10

7 February 2019 in JMIR Medical Informatics
Verified
Journal Article
Open access
AAAzraa Amroze
Azraa Amroze
TFTerry S Field
Terry S Field
HFHassan Fouayzi
Hassan Fouayzi
DSDevi Sundaresan
Devi Sundaresan
LBLaura Burns
Laura Burns
SCSarah L Cutrona
Sarah L Cutrona
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Electronic health record (EHR) access and audit logs record behaviors of providers as they navigate through the EHR. These data can be used to better understand provider responses to EHR-based clinical decision support (CDS), shedding light on why CDS is (and is not) effective. Objective: To determine the feasibility of using EHR access and audit logs to track primary care physician (PCP) opening of and response to non-interruptive alerts delivered to EHR InBaskets. Methods: We conducted a descriptive study to assess use of EHR log data to track provider behavior. We analyzed data recorded following opening of 799 non-interruptive alerts sent to 75 PCPs’ InBaskets as part of a prior randomized controlled trial. Three types of alerts highlighted new medication concerns for older patients post-hospital discharge: information-only (593), medication recommendations (37), and test recommendations (169). We sought log data to identify timing of alert opening and timing and type of PCPs’ subsequent EHR actions (immediate actions and those taken by the end of the following day). We performed multivariate analyses examining associations between alert type, patient characteristics, provider characteristics, and contextual factors and likelihood of immediate or subsequent PCP action (general, medication-specific, or laboratory-specific actions). We describe challenges and strategies for log data use. Results: We successfully identified the required data in EHR access and audit logs. Our descriptive study found that one-third (33.8%) of alerts opened by the addressed PCP (208/616) were followed by immediate EHR action by the PCP. Two-thirds (67.3%) of all alerts (538/799) had evidence of action by the end of the following day. Compared to information-only alerts, the odds ratios (OR) of immediate action for medication recommendation were 4.03 [95% confidence interval (CI) 1.67- 9.72]; the OR for test recommendation alerts was 2.14 [95% CI 1.38-3.32]. Compared to information-only alerts, OR of medication-specific action by end of the following day were significantly greater for medication recommendations (5.59 [95% CI 2.42-12.94]) and test recommendations (1.71 [95% CI 1.09-2.68]); we found a similar pattern for OR of laboratory-specific action. We encountered 2 main challenges. (1) Capturing a historical snapshot of EHR status (e.g. number of InBasket messages at time of alert delivery) required incorporation of data generated many months prior along with longitudinal follow-up. (2) Accurately interpreting data elements required iterative work by a physician/data manager team, taking action within the EHR then examining the audit log to identify the corresponding documentation. Conclusions: EHR log data could inform future efforts and provide valuable information during development and refinement of CDS interventions. To address challenges, use of these data should be planned in advance of implementing an EHR-based study.

1 June 2010 in Medical Care
Verified
Journal Article
Closed access
BBBecky A. Briesacher
Becky A. Briesacher
DRDennis Ross-Degnan
Dennis Ross-Degnan
AWAnita K. Wagner
Anita K. Wagner
HFHassan Fouayzi
Hassan Fouayzi
FZFang Zhang
Fang Zhang
SSStephen B. Soumerai
Stephen B. Soumerai
Background: Evaluating the adequacy of Medicare prescription drug program (Part D) and its low-income subsidy (LIS) requires a comprehensive understanding of drug spending in relation to household resources. Objective: To estimate out-of-pocket health care costs in the year before Part D, in context of total household spending, health status, and LIS eligibility. Research Design: Nationally representative cross-sectional study. Subjects: Two thousand two hundred thirty-one Medicare families in the 2005/2006 Health and Retirement Study. Methods: We assessed health care costs as a share of household resources remaining after spending on essential housing, food, personal care, and transportation. Burdensome health care costs were defined as exceeding 40% of nonessential resources. We used logistic regressions to assess the probability of incurring burdensome health expenditures, controlling for LIS eligibility. Results: In the year before Part D, more than half of Medicare families [56.0%; 95% confidence interval (CI): 55.3–59.9] experienced burdensome health care costs. Families in poor health allocated a median of 68.1% [interquartile range (IQR): 35.1–82.9] of nonessential resources to health care (compared with 34.0% median; IQR 11.9–52.2 among families in excellent health, P < 0.011). Most (64%) out-of-pocket health care spending was allocated to health insurance premiums and medications. As many as 26% of Medicare families had burdensome health care costs but were not eligible for LIS assistance. Conclusions: Before Part D, burdensome health care expenditures were common in Medicare families. Our estimates of Part D and LIS benefits indicate a limited scope of relief.